Compare iShares Core High Dividend ETF (HDV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core High Dividend ETF trades at $28.17, while Vertex Pharmaceuticals Incorporated trades at $484.27 (market cap $121.95B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| HDV | VRTX | |
|---|---|---|
52-Week High | $28.36 | $529.59 |
52-Week Low | $23.64 | $366.54 |
Market Cap | — | $121.95B |
Sector | — | Health |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a 3.0% dividend yield, with recent payouts of $0.19 and $0.09 per share. News coverage highlights HDV's defensive sector focus and competitive expense ratio compared to peers like SCHD and VYM, though some analysts note concentration risk in energy holdings.
Outlook remains cautiously positive given HDV's low volatility and income appeal, but investors face risks from oil price sensitivity and modest dividend growth. The ETF's quality screen provides stability, yet sector concentration may limit upside if energy underperforms.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
